Contact Us | Find An Expert

Find an Expert
a

What is Glaucoma?

Glaucoma is a progressive disease of the eye that if left untreated, can eventually lead to blindness.

Learn More

iStent inject® W

iStent inject W can help restore your eye’s natural drainage system to potentially lower intraocular pressure (IOP) inside your eye.

Learn More

Patient Stories

“It’s a scary thing. I would encourage people to look into the prospect of how their glaucoma can be treated.” – George

View Stories

Find a Provider

Find out if you are a candidate for iStent inject W by speaking with an iStent inject W physician in your area today.

View Stories

Cataract surgery and glaucoma therapy – all in one procedure. Adding iStent inject® W to your cataract surgery can provide a number of benefits.

Unlike medications, which require regular doses, iStent inject® W is a medical device that is designed to work continuously.

iStent inject® W may help reduce the number of glaucoma medications needed, at your physician’s discretion.

iStent inject W is built on a proven technology platform shown to potentially allow patients to achieve lower intraocular pressure (IOP) after the procedure, with an excellent overall safety profile.1,2

With Glaucoma
Without Glaucoma
With Glaucoma
Without Glaucoma

Drag slider in either direction to simulate a glaucoma patient’s vision.

Individual outcomes may vary. The depiction may not reflect the typical glaucoma patient’s experience and the timeline may vary. It is not intended to represent of guarantee that anyone will have the same or similar outcomes.

What is Glaucoma?

Glaucoma is a progressive disease of the eye that if left untreated, can eventually lead to blindness. Glaucoma is commonly associated with increased intraocular pressure (IOP) in the eye due to an imbalance in production and outflow of aqueous humor, which is the fluid produced by the eye. Glaucoma is asymptomatic – meaning it occurs without noticeable symptoms appearing—and can often go undiagnosed without proper checkups, and worsen over time.

Learn More

What are my Treatment Options?

View Options

What is iStent inject® W?

iStent inject® W is one of the smallest devices known to be implanted in the human body and it can have benefits for glaucoma patients with cataracts. The iStent inject® W stents create two bypasses, or openings, between the front part of your eye and its natural drainage pathway, restoring your eye’s natural ability to drain fluid and reducing your intraocular pressure (IOP).

See How It Works

Is iStent inject® W Right for Me?

Implanted during cataract surgery, iStent inject® W can effectively lower intraocular pressure (IOP), one of the most important risk factors for glaucoma, and may reduce your reliance on glaucoma medication at the discretion of an eye care professional.

Find Out Now

"It's a scary thing. It's a silent, sort of, invasion, and I want people to know that there is something that you should do and can do about the effects. I would encourage people to look into the prospect of how their glaucoma can be treated."

Testimonial Item

George

"If you have a doctor that is caring and knowledgeable, just follow the protocol that they laid out. I had no anxiety about my treatment. I understood it, because my doctor laid it out. Even with procedures, tests, my doctor said, 'This is what you need to do.' I probably owe my eyesight to her."

Testimonial Item

Deborah

Hear from Others with Glaucoma

view patient stories

Are You Considering the iStent inject® W Procedure?

Find out if you are a candidate for iStent inject® W by speaking with an iStent inject® W physician in your area today.

Find a Physician

Stay Connected

Sign up for our newsletter to receive the latest information about glaucoma, new treatments, research findings and more!

Glaukos will use the information you provide on this form to be in touch with you.

Consent(Required)
This field is for validation purposes and should be left unchanged.

1. iStent inject® Trabecular Micro-Bypass System: Directions for Use, Part # 45-0176.
2. Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther. 2018 Dec; 7(2): 405-415.

PM-US-0591

INDICATION FOR USE
The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma.

CONTRAINDICATIONS
The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS
Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION
The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure (IOP). The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated intraocular pressure (IOP) > 24 mmHg or unmedicated intraocular pressure (IOP) < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

ADVERSE EVENTS
Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

CAUTION
Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

Text Optimizer